| Type | Species | Target | Product/Company | License date/ country | Route of administration | Benefits |
| Prophylactic vaccine | Horses | West Nile Virus | West Nile-Innovator®/ Fort Dodge Animal Health | 2005 USA | IM1 | Production of protective antibodies |
| Prophylactic vaccine | Salmon | Infectious haematopoietic necrosis virus (IHNV) | Apex-IHN®/Novartis Animal Health | 2005 Canada | IM | Stimulation of innate and adaptive immune responses improving the welfare and product yield |
| Immunotherapy of cancer | Dogs | Melanoma | Oncept™/Merial | 2010 USA | ID2 needle-free. | Production of antibodies capable of preventing the progress of the disease and prolonging the animal’s life |
| Gene therapy | Swine | Growth hormone releasing hormone (GHRH) | LifeTide® SW5/VGX™ Animal Health | 2008 Australia | IM followed by electroporation | Decrease in perinatal mortality and morbidityincrease of the number of pigs weaned per sow and productivity |